Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Allison Wey - SVP, IR and Corporate Communications Paul Edick - Chairman and CEO Steve Pieper - CFO Conference Call Participants Roanna Ruiz - SVB Leerink Vamil Divan - Mizuho Securities David Amsellem - Piper Sandler Operator Hello everyone. And welcome to the Xeris Biopharma Fourth Quarter 2021 Financial Results Conference Call and Webcast. My name is Seth and I will be the operator ...

Xeris Biopharma (Nasdaq: XERS) A biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology February 2022 Copyright ©2017-2021 Xeris Pharmaceuticals, Inc. All rights reserved. Forward-looking statements 2 Any statements in this presentation about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the market and therapeutic potential of its products and product cand ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve Pieper - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Oren Livnat - H.C. Wainwright David Steinberg - Jefferies Alexandre Bouilloux - Mizuho Securities Kelley Prince - Close Concerns Operator Welcome to ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | Forward-looking statements 2 This document contains forward‐looking statements relating to the Company's strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated ...

Strongbridge Biopharma plc (SBBP) Q1 2021 Earnings Conference Call May 12, 2021 8:30 AM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - CEO Fredric Cohen - CMO Richard Kollender - President and CFO Scott Wilhoit - CCO Officer Conference Call Participants Roger Song - Jefferies Annabel Samimy - Stifel Jonathan Wolleben - JMP Securities Robin Garner - Craig-Hallum Operator Good morning ladies and gentlemen and welcome to the Strongbridge Biopharma Plc Corporate Update an ...

| --- | --- | |----------------------|-------| | | | | | | | Unlocking the | | | potential of today's | | | | | | medicines for | | | profound impact | | March 2021 Xeris Pharmaceuticals, Inc. ©2017-2020 All Rights Reserved Forward-looking Statements 2 This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the rate and degree of market acceptance and clinical utility of Gvoke®, the market and the the ...

Strongbridge Biopharma plc (SBBP) Q4 2020 Earnings Conference Call March 3, 2021 8:30 AM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - Chief Executive Officer Fredric Cohen - Chief Medical Officer Richard Kollender - Chief Financial Officer and Chief Operating Officer Scott Wilhoit - Chief Commercial Officer Conference Call Participants Chris Howerton - Jefferies Hartaj Singh - Oppenheimer & Company Annabel Samimy - Stifel Jonathan Wolleben - JMP Securities Robin Gar ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | Forward-looking statements 2 This document contains forward‐looking statements relating to the Company's strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | Forward-looking statements 2 This document contains forward‐looking statements relating to the Company's strategy, objectives, business development plans, financial position, clinical development, regulatory plans and revenue guidance. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated ...

Strongbridge Biopharma plc (SBBP) Q3 2020 Earnings Conference Call October 29, 2020 4:30 PM ET Company Participants Lindsay Rocco - Elixir Health, Public Relations John Johnson - CEO Fred Cohen - Chief Medical Officer Rob Lutz - CFO Scott Wilhoit - Chief Commercial Officer Rich Kollender - COO Conference Call Participants Annabel Samimy - Stifel Chris Howerton - Jefferies Justin Kim - Oppenheimer Jonathan Wolleben - JMP Securities Operator Good afternoon, ladies and gentlemen and welcome to Strongbridge Bio ...